Vontobel Holding Ltd. Sells 92,362 Shares of IQVIA Holdings Inc. $IQV

Vontobel Holding Ltd. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 458,068 shares of the medical research company’s stock after selling 92,362 shares during the quarter. Vontobel Holding Ltd. owned about 0.27% of IQVIA worth $103,253,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Boston Partners purchased a new stake in shares of IQVIA in the third quarter worth about $676,698,000. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter worth about $497,445,000. AQR Capital Management LLC lifted its holdings in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after buying an additional 475,557 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.0%

Shares of NYSE IQV opened at $181.10 on Friday. IQVIA Holdings Inc. has a one year low of $153.01 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm’s 50 day simple moving average is $173.56 and its two-hundred day simple moving average is $193.68. The stock has a market capitalization of $30.23 billion, a P/E ratio of 22.44, a PEG ratio of 1.55 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business earned $2.70 earnings per share. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IQV shares. Evercore reissued an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research note on Thursday, May 7th. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.